Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 11/20 | 0.53 |
| ▸ | INSR | P06213 | 7/20 | 0.53 |
| ▸ | IGF1R | P08069 | 4/20 | 0.53 |
| ▸ | EML4 | Q9HC35 | 5/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.52 |
| ▸ | RET | P07949 | 5/20 | 0.52 |
| ▸ | ROS1 | P08922 | 5/20 | 0.52 |
| ▸ | FLT3 | P36888 | 5/20 | 0.52 |
| ▸ | SYK | P43405 | 3/20 | 0.52 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | PRKCG | P05129 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447250 | 1.00 | ALK (0.53) | ALKINSRIGF1REML4HSP90AA1 | |
| SCHEMBL12682537 | 0.90 | ALK (0.54) | ALKINSRIGF1REML4HSP90AA1 | |
| SCHEMBL16887726 | 0.90 | ALK (0.56) | ALKINSRIGF1REML4HSP90AA1 | |
| SCHEMBL30875991 | 0.86 | CYP1A2 (0.54) | ALKINSRIGF1REML4HSP90AA1 | |
| SCHEMBL3676371 | 0.86 | ALK (0.53) | ALKINSRIGF1REML4RET | |
| SCHEMBL589318 | 0.84 | ALK (0.50) | ALKINSRIGF1REML4HSP90AA1 | |
| SCHEMBL30957440 | 0.84 | ALK (0.50) | ALKINSRIGF1REML4HSP90AA1 | |
| SCHEMBL31391684 | 0.82 | HSP90AA1 (0.51) | ALKINSRIGF1REML4HSP90AA1 | |
| SCHEMBL24900589 | 0.81 | ALK (0.50) | ALKINSRIGF1REML4RET | |
| SCHEMBL3512243 | 0.81 | ALK (0.48) | ALKINSRIGF1REML4RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3654952-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ENTRECTINIB | Ignyta, Inc. (US) | 2020-05-27 | — | — | EP | claimed |
| WO-2019018570-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ENTRECTINIB | IGNYTA, INC. (US) | 2019-01-24 | — | — | WO | claimed |
| EP-3233840-A1 | HETEROCYCLIC DERIVATIVES MODULATING ACTIVITY OF CERTAIN PROTEIN KINASES | Eudendron S.r.l. (IT) | 2017-10-25 | — | — | EP | claimed |
| WO-2016096709-A1 | HETEROCYCLIC DERIVATIVES MODULATING ACTIVITY OF CERTAIN PROTEIN KINASES | EUDENDRON S.R.L. (IT) | 2016-06-23 | — | — | WO | claimed |
| CN-115916771-A | Multi-target antitumor compound and preparation method and application thereof | 浙江华海药业股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-111225662-B | Pharmaceutical compositions and dosage forms | 伊尼塔公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-114206341-A | Novel pharmaceutical formulations | 豪夫迈·罗氏有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021197467-A1 | MULTI-TARGET ANTI-TUMOR COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海华汇拓医药科技有限公司 | 2021-10-07 | — | — | WO | disclosed |
| EP-3697390-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | Ignyta, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| CN-111225662-A | Pharmaceutical compositions and dosage forms | 伊尼塔公司 | 2020-06-02 | — | — | CN | disclosed |
| CN-110913842-A | Pharmaceutical compositions comprising enretinib | 伊尼塔公司 | 2020-03-24 | — | — | CN | disclosed |
| US-10398693-B2 | Pharmaceutical compositions and dosage forms | IGNYTA, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| WO-2019077506-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | IGNYTA, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190022089-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | IGNYTA, INC. (US) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398693-B2 | Pharmaceutical compositions and dosage forms | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | ALK 1518/4885INSR 1236/4885IGF1R 3317/4885 |
| US-20190022089-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | ALK 1518/4885INSR 1236/4885IGF1R 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.